Advertisement

Milford company Spring Bank Pharmaceuticals Inc. has landed a $3.9 million grant from the National Institutes of Health to further develop a drug candidate to treat Hepatitis B infections.

The five-year grant came from the NIH division, the National Institute of Allergy and Infectious Diseases, and becomes the fourth federal grant the company has taken in based on its platform technology, for a total of more than $12 million, officials said in a release.

SOURCE

Advertisement
Advertisement